155 related articles for article (PubMed ID: 38296607)
1. Influence of Staphylococcal enterotoxin-specific IgE sensitization on therapeutic efficacy of omalizumab therapy in severe asthma.
Weng CM; Wu WC; Lee MJ; Chen MC; Chou CL; Lin CY; Chung KF; Kuo HP
Respirology; 2024 Mar; 29(3):252-255. PubMed ID: 38296607
[No Abstract] [Full Text] [Related]
2. Omalizumab in the Therapy of Pediatric Asthma.
Poddighe D; Brambilla I; Licari A; Marseglia GL
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):103-109. PubMed ID: 29714140
[TBL] [Abstract][Full Text] [Related]
3. Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma.
Mizuma H; Tanaka A; Uchida Y; Fujiwara A; Manabe R; Furukawa H; Kuwahara N; Fukuda Y; Kimura T; Jinno M; Ohta S; Yamamoto M; Matsukura S; Adachi M; Sagara H
Int Arch Allergy Immunol; 2015; 168(3):165-72. PubMed ID: 26790100
[TBL] [Abstract][Full Text] [Related]
4. Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma.
Bachert C; van Steen K; Zhang N; Holtappels G; Cattaert T; Maus B; Buhl R; Taube C; Korn S; Kowalski M; Bousquet J; Howarth P
J Allergy Clin Immunol; 2012 Aug; 130(2):376-81.e8. PubMed ID: 22738677
[TBL] [Abstract][Full Text] [Related]
5. The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.
Bartuzi Z; Bodzenta-Łukaszyk A; Kuna P; Kupryś-Lipińska I; Niżankowska-Mogilnicka E; Samoliński B
Pneumonol Alergol Pol; 2015; 83(4):335-8. PubMed ID: 26166795
[No Abstract] [Full Text] [Related]
6. Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma.
Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Paggiaro PL
J Investig Allergol Clin Immunol; 2017; 27(6):388-391. PubMed ID: 29199967
[No Abstract] [Full Text] [Related]
7. Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab.
Gon Y; Ito R; Maruoka S; Mizumura K; Kozu Y; Hiranuma H; Iida Y; Hikichi M; Shikano S; Hashimoto S
Allergol Int; 2018 Apr; 67(2):283-285. PubMed ID: 28927962
[No Abstract] [Full Text] [Related]
8. IgE-mediated asthma: New revelations and future insights.
Djukanovic R; Hanania N; Busse W; Price D
Respir Med; 2016 Mar; 112():128-9. PubMed ID: 26577335
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab's Impact on Total and Allergen-Specific IgE Levels: A Polyclonal Story.
Eckl-Dorna J
Int Arch Allergy Immunol; 2016; 169(2):69-70. PubMed ID: 27035498
[No Abstract] [Full Text] [Related]
10. Eosinophilic Esophagitis Onset Despite Six Years' Treatment With Omalizumab in an Asthmatic Patient: No Protective Effect for Anti-IgE Therapy?
Franceschini L; Macchiarelli R; Biviano I; Farsi A
Am J Gastroenterol; 2021 Jul; 116(7):1560. PubMed ID: 33852452
[No Abstract] [Full Text] [Related]
11. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies.
Palomares Ó; Sánchez-Ramón S; Dávila I; Prieto L; Pérez de Llano L; Lleonart M; Domingo C; Nieto A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635659
[TBL] [Abstract][Full Text] [Related]
12. A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.
Johansson SGO; Lilja G; Hallberg J; Nopp A
Immun Inflamm Dis; 2018 Sep; 6(3):382-391. PubMed ID: 29737044
[TBL] [Abstract][Full Text] [Related]
13. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
14. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab effectiveness is independent of Staphylococcal Enterotoxin sensitization.
Migueres N; Poirot A; Zhang N; Bachert C; de Blay F
Respir Med Res; 2023 Jun; 83():100986. PubMed ID: 36630776
[No Abstract] [Full Text] [Related]
16. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
[TBL] [Abstract][Full Text] [Related]
17. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
18. Pediatric use of omalizumab for allergic asthma.
Pajno GB; Castagnoli R; Arasi S; Licari A; Caminiti L; Marseglia GL
Expert Opin Biol Ther; 2020 Jul; 20(7):695-703. PubMed ID: 32241196
[TBL] [Abstract][Full Text] [Related]
19. Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?
Novosad J; Krčmová I
Int J Immunopathol Pharmacol; 2020; 34():2058738420942386. PubMed ID: 32689848
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI.
Maggi L; Rossettini B; Montaini G; Matucci A; Vultaggio A; Mazzoni A; Palterer B; Parronchi P; Maggi E; Liotta F; Annunziato F; Cosmi L
Eur J Immunol; 2018 Dec; 48(12):2005-2014. PubMed ID: 30252930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
